Analysts called the acquisition a good fit for Axogen but said the company’s plans to finance the deal with a public stock offering could be a point of contention for investors.
Axogen to buy BioCircuit Technologies for $200M
Analysts called the acquisition a good fit for Axogen but said the company’s plans to finance the deal with a public stock offering could be a point of contention for investors.